Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Jan;136(2):273-280.
doi: 10.1007/s11060-017-2649-8. Epub 2017 Nov 14.

Local alkylating chemotherapy applied immediately after 5-ALA guided resection of glioblastoma does not provide additional benefit

William Sage  1 , Mathew Guilfoyle  1 , Catriona Luney  1 , Adam Young  1 , Rohitashwa Sinha  1 , Donatella Sgubin  2 , Joseph H McAbee  3 , Ruichong Ma  4 , Sarah Jefferies  5 , Rajesh Jena  5 , Fiona Harris  5 , Kieren Allinson  6 , Tomasz Matys  7 , Wendi Qian  8 , Thomas Santarius  1 , Stephen Price  1 , Colin Watts  9   10
Affiliations

Local alkylating chemotherapy applied immediately after 5-ALA guided resection of glioblastoma does not provide additional benefit

William Sage et al. J Neurooncol. 2018 Jan.

Abstract

Grade IV glioma is the most common and aggressive primary brain tumour. Gross total resection with 5-aminolevulinic acid (5-ALA) guided surgery combined with local chemotherapy (carmustine wafers) is an attractive treatment strategy in these patients. No previous studies have examined the benefit carmustine wafers in a treatment programme of 5-ALA guided resection followed by a temozolomide-based chemoradiotherapy protocol. The objective of this study was to examine the benefit of carmustine wafers on survival in patients undergoing 5-ALA guided resection. A retrospective cohort study of 260 patients who underwent 5-ALA resection of confirmed WHO 2007 Grade IV glioma between July 2009 and December 2014. Survival curves were calculated using the Kaplan-Meier method from surgery. The log-rank test was used to compare survival curves between groups. Cox regression was performed to identify variables predicting survival. A propensity score matched analysis was used to compare survival between patients who did and did not receive carmustine wafers while controlling for baseline characteristics. Propensity matched analysis showed no significant survival benefit of insertion of carmustine wafers over 5-ALA resection alone (HR 0.97 [0.68-1.26], p = 0.836). There was a trend to higher incidence of wound infection in those who received carmustine wafers (15.4 vs. 7.1%, p = 0.064). The Cox regression analysis showed that intraoperative residual fluorescent tumour and residual enhancing tumour on post-operative MRI were significantly predictive of reduced survival. Carmustine wafers have no added benefit following 5-ALA guided resection. Residual fluorescence and residual enhancing disease following resection have a negative impact on survival.

Keywords: 5-Aminolevulinic acid; Carmustine; Glioma; Neurosurgery.

PubMed Disclaimer

Conflict of interest statement

No conflict of interest declared.

Figures

Fig. 1
Fig. 1
Comparison of survival for patients treated with or without carmustine wafers. Kaplan–Meier survival curves for patients having 5-ALA guided resection without carmustine wafers (No CW) and 5-ALA resection with carmustine wafers (CW). a Unadjusted analysis of the two patient groups. b Groups matched for baseline covariates by propensity score (see text for details). c Survival curves adjusted for baseline covariates and post-operative treatment by inverse probability weighting. HR hazard ratio for the log-rank test
Fig. 2
Fig. 2
Effect on Survival of Residual Enhancing Tumour on MRI. Kaplan–Meier survival curves, adjusted for baseline covariates and post-operative treatment, for patients with and without evidence of residual enhancing tumour on post-operative MRI within 72 h from surgery. HR hazard ratio for the log-rank test
See this image and copyright information in PMC

Comment in

References

    1. Burnet NG, Jefferies SJ, Benson RJ, Hunt DP, Treasure FP. Years of life lost (YLL) from cancer is an important measure of population burden—and should be considered when allocating research funds. Br J Cancer. 2005;92(2):241–245. doi: 10.1038/sj.bjc.6602321. - DOI - PMC - PubMed
    1. Weller M, van den Bent M, Hopkins K, et al. EANO guideline for the diagnosis and treatment of anaplastic gliomas and glioblastoma. Lancet Oncol. 2014;15(9):e395–e403. doi: 10.1016/S1470-2045(14)70011-7. - DOI - PubMed
    1. Stupp R, Brada M, van den Bent MJ, Tonn JC, Pentheroudakis G, on behalf of the ESMO Guideline Working Group High-grade glioma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2014;25(Suppl 3):iii93–101. doi: 10.1093/annonc/mdu050. - DOI - PubMed
    1. Stummer W, Meinel T, Ewelt C, et al. Prospective cohort study of radiotherapy with concominant and adjuvant temozolomide chemotherapy for glioblastoma patients with no or minimal residual enhancing tumor load after surgery. J Neurooncol. 2012;108(1):89–97. doi: 10.1007/s11060-012-0798-3. - DOI - PMC - PubMed
    1. Kreth FW, Thon N, Simon M, et al. Gross total but not incomplete resection of glioblastoma prolongs survival in the era of radiochemotherapy. Ann Oncol. 2013;24(12):3117–3123. doi: 10.1093/annonc/mdt388. - DOI - PubMed

LinkOut - more resources